<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/724AD253-7539-4122-9AA6-1C1302D758F4"><gtr:id>724AD253-7539-4122-9AA6-1C1302D758F4</gtr:id><gtr:name>Inocardia Limited</gtr:name><gtr:address><gtr:line1>TECHNOCENTRE , PUMA WAY</gtr:line1><gtr:city>COVENTRY</gtr:city><gtr:postCode>CV1 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/724AD253-7539-4122-9AA6-1C1302D758F4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>724AD253-7539-4122-9AA6-1C1302D758F4</gtr:id><gtr:name>Inocardia Limited</gtr:name><gtr:address><gtr:line1>TECHNOCENTRE , PUMA WAY</gtr:line1><gtr:city>COVENTRY</gtr:city><gtr:postCode>CV1 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>98407.0</gtr:offerGrant><gtr:projectCost>164011.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/678E8A69-BD79-4D57-B24E-BC7578D11BC0"><gtr:id>678E8A69-BD79-4D57-B24E-BC7578D11BC0</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Maddock</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710533"><gtr:id>9458384D-B6BF-4E44-8ABB-529B711979F3</gtr:id><gtr:title>InoCardia: Cellular Work-Loop Proof of Concept</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710533</gtr:grantReference><gtr:abstractText>Adverse effect of drugs on the cardiovascular system is a major cause for compounds failing
in both non-clinical and clinical studies. Indeed, some of these adverse effects may only be
currently detected after the compound has been granted marketing approval and many
thousands of patients treated. Thus such effects represent a significant issue for human health
and very high costs for the pharmaceutical industry. Although adverse drug effects on the
cardiovascular system may be due to many effects, one area of great concern is the effect of
drugs on the force of contraction of the heart. Some drugs can reduce the force of contractions
and cause symptoms similar to heart failure in susceptible patients whilst others can increase
it resulting in an imbalance between the amount of oxygen needed by the heart and that
supplied by the blood.
Currently, testing for drug effects on the force of contraction of the heart is very much
dependent on the use of animals (in-vivo tests) and / or low throughput assays using isolated
tissues (in-vitro tests). Given the nature of these studies testing is often conducted very late in
the drug discovery process. Furthermore, the predictive value of the available tests for human
risk is limited. Thus, there is a need for more predictive assays with much greater throughput
that can be used to select compounds with much less effect on the heart.
The goal of this project is to test the concept of a higher throughput functional cardiac cell
contractile assay under truly physiological conditions. It will essentially advance the
information on how the heart behaves functionally and enable us to test inotropic drugs in
these conditions. If successful, we aim to develop a higher throughput assay to test many
compounds per week enabling selection of compounds for clinical trials that have less liability
to adversely affect the contractility of the heart.</gtr:abstractText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>98407</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710533</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>